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Parkinson’s disease (PD) is a neurodegenerative disease with both motor and non-motor
manifestations. Hyposmia is one of the early non-motor symptoms, which can
precede motor symptoms by several years. The relationship between hyposmia and
PD remains elusive. Olfactory bulb (OB) pathology shows an increased number of
olfactory dopaminergic cells, protein aggregates and dysfunction of neurotransmitter
systems. In this study we examined tissue levels of dopamine (DA) and serotonin
(5-hydroxytryptamine, 5-HT) and their metabolites, of noradrenaline (NA) and of
the amino acid neurotransmitters aspartate, glutamate, taurine and γ-aminobutyric
acid in OBs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated Macaca
fascicularis in different stages, including monkeys who were always asymptomatic,
monkeys who recovered from mild parkinsonian signs, and monkeys with stable
moderate or severe parkinsonism. DA was increased compared to controls, while
neither NA and 5-HT nor the amino acid neurotransmitters were significantly changed.
Furthermore, DA increased before stable motor deficits appear with +51% in
asymptomatic and +96% in recovered monkeys. Unchanged DA metabolites suggest
a special metabolic profile of the newly formed DA neurons. Significant correlation of
homovanillic acid (HVA) with taurine single values within the four MPTP groups and
of aspartate with taurine within the asymptomatic and recovered MPTP groups, but
not within the controls suggest interactions in the OB between taurine and the DA
system and taurine and the excitatory neurotransmitter triggered by MPTP. This first
investigation of OB in various stages after MPTP administration suggests that the
DA increase seems to be an early phenomenon, not requiring profound nigrostriatal
neurodegeneration or PD symptoms.
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INTRODUCTION
The olfactory bulb (OB) is a neuronal structure of the forebrain being the most rostral part of the
adult brain in rodents, but situated on the inferior side of the forebrain in primates. According
to the prosomeric model of the brain holding that the brain is formed by an uninterrupted series
of transverse subunits of the neural tube, it is dorsal of the prospective anterior commissure which is
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the most rostral point of the neural tube (Puelles and Rubenstein,
2015). It functions as a processor of odor information by
forming a sophisticated network of multiple types of neurons
transmitting the information to the olfactory cortex. The
monoamine neurotransmitters dopamine (DA), noradrenaline
(NA) and serotonin (5-hydroxytryptamine, 5-HT) have been
shown to influence odor processing. DA is the neurotransmitter
of an intrinsic subpopulation of neurons within the glomerular
cell layer and affects odor discrimination learning in rats
(Escanilla et al., 2009). Recently, a direct axonal dopaminergic
projection from the substantia nigra (SN) to the core of the
OB was described and suggested to facilitate the perception of
odorants (Höglinger et al., 2015). Noradrenergic fibers from the
locus coeruleus and serotoninergic fibers from the raphe nucleus
project to all layers of the OB (McLean and Shipley, 1987, 1991;
Gómez et al., 2005). NA modulates odor habituation (Guerin
et al., 2008) and 5-HT regulates odor inputs in the OB (Petzold
et al., 2009). For all monoamines effects on synaptic transmission
in the OB were also shown (Jiang et al., 1996; Berkowicz and
Trombley, 2000; Petzold et al., 2009).
Importantly, olfactory dysfunction is a frequent non-motor
symptom of Parkinson’s disease (PD). There is structural
pathology observed in the OB of individuals with PD. Lewy
body pathology was also detected in the OB in patients with
incidental Lewy body disease and PD (Attems et al., 2014;
Saito et al., 2016). The OB volume was found reduced in
several studies (Wang et al., 2011; Brodoehl et al., 2012; Li
et al., 2016), whereas the number of DA neurons was increased
in some reports (Huisman et al., 2004, 2008; Mundiñano
et al., 2011). Dopaminergic neurogenesis also increased in OB
following i.p. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) intoxication in mice (Yamada et al., 2004) and after
nigrostriatal DA depletion by 6-hydroxydopamine injection
in the SN in mice and in the medial forebrain bundle in rat
(Winner et al., 2006; Chiu et al., 2014; Höglinger et al., 2015).
In addition, in the α-synuclein A53T transgenic mice there
was a decrease of cholinergic neurons and acetylcholinesterase
activity in mitral cell layer and an increase of dopaminergic
neurons and tyrosine hydroxylase protein in the glomerular
layer at 10 months (Zhang et al., 2015). Tyrosine hydroxylase
expression was also found increased in the OBs of transgenic
rats with α-synuclein mutations (Lelan et al., 2011). Thus,
nigrostriatal DA depletion through different approaches appears
to increase dopaminergic neurogenesis in the OB. The increased
number of DA neurons could be a compensatory change for
the lack of inhibitory modulation of mitral cells by cholinergic,
noradrenergic and serotonergic olfactory afferents which are
often reduced in neurodegenerative diseases (Mundiñano
et al., 2011). Similarly, increased dopaminergic tone in the
OB of PD patients could reflect a compensatory mechanism
created by the early degeneration of other neurotransmitter
systems and might contribute to the olfactory dysfunction
exhibited by patients with neurodegenerative disorders
(Bédard et al., 2002; Winner et al., 2006; Mundiñano et al.,
2011).
In MPTP parkinsonian monkeys the number of olfactory
dopaminergic neurons was reported to be nearly doubled as
compared to controls (Belzunegui et al., 2007) and, in fact,
cholinergic OB innervation was decreased in this model as
well as in patients with PD (Mundiñano et al., 2013). Here,
we have examined the OBs of Macaca fascicularis monkeys in
four motor states after progressive parkinsonism induced by
repeated administration of small doses of MPTP corresponding
to different degrees of nigro-striatal lesion and DA depletion
(Blesa et al., 2012).
MATERIALS AND METHODS
Animals
Experiments were performed using OBs from 37 male
cynomolgus monkeys (Macaca fascicularis, RC Hartelust,
Tilburg, Netherlands, mean age 5.2 ± 0.9 years, mean weight
3.6 ± 0.65 kg). Animals were housed in primate cages, singly or
in pairs, under controlled conditions of air exchange (16 l/min),
humidity (50%) and light/dark cycles (8 am to 8 pm); food and
water were available ad libitum. All procedures were performed
according to the European Council Directive 86/609/EEC and in
accordance with the Society for Neuroscience Policy on the Use
of Animals in Neuroscience Research. The Ethics Committee
for Animal Testing of the University of Navarra approved the
experimental design.
Experimental Protocol
Fourteen of the 37monkeys were used as controls. The remaining
23 monkeys were treated with MPTP hydrochloride (Sigma,
St Louis, MO, USA) using a low-dose regimen (0.5 mg/kg in
saline administered intravenously once every 2 weeks) to obtain
partial, slowly progressing degeneration of the dopaminergic
nigro-striatal system (Blesa et al., 2010, 2012). The number
of doses for each animal ranged from 1 to 16, and the total
dose from 0.5 mg/kg to 8 mg/kg. Such a wide range in
number and total dose of MPTP was determined by individual
susceptibility to the toxin, which varies considerably when a
slow intoxication protocol is employed. This in turn allows
for different degrees of motor deficit and nigro-striatal lesion.
Motor performance was tested using the Kurlan Scale (Blesa
et al., 2012). To satisfy the classification criteria, each animal
had to remain stable for at least 1 month in the corresponding
motor state before being classified in a given group (Taylor
et al., 1997; Blesa et al., 2012). The striatal biochemical
characterization of these animals was published before (Blesa
et al., 2012).
Neurochemical Analysis
Samples were ultrasonicated in 30 volumes of perchloric
acid, sodium bisulfite and 3,4-dihydroxybenzylamine as
internal standard (final concentration 0.1 M, 0.4 mM and
20 µg/l, respectively) and centrifuged at 16,100× g for
10 min. For determination of 3,4-dihydroxyphenylacetic
acid (DOPAC), 5-HT, 5-hydroxyindolacetic acid (5-HIAA)
and homovanillic acid (HVA) 100 µl of supernatant was
injected directly into a HPLC system equipped with a
LiChroCARTr 250-4, RP18µ, 5 µm (VWR) column and
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a BAS (Bioanalytical System) electrochemical detector. The
mobile phase consisted of 0.1 M sodium acetate buffer, pH
4.3, containing 1 mM EDTA, 0.2 mM l-heptane sulfonic acid,
0.1% triethylamine, 0.2% tetrahydrofurane and 10% methanol.
For determination of DA and NA, aliquots of the supernatant
were extracted with alumina oxide and injected into a HPLC
system as described previously (Pifl et al., 1991) with minor
modifications (LiChroCARTr 250-4, RP18µ, 5 µm column,
HP Programmable Electrochemical Detector 1049A, mobile
phase with 9% methanol). For determination of γ-aminobutyric
acid (GABA), aspartate, glutamate, taurine and glycine the
supernatant was diluted with H2O (final dilution 1:2000).
One-hundred micro liter were mixed with 50 µl of OPA-reagent
(25 mg o-phthalaldehyde dissolved in a mixture of 0.5 ml
methanol, 25 µl 1.meercaptoethanol and 4.5 ml 0.4 sodium
borate, pH 11) and after a reaction time of 2 min, 20 µl were
injected by an autosampler (AS950, Jasco). The HPLC system
consisted of a RP-18 column (Chromolith-Peformance RP-
18e, 100 × 4.6 mm, Merck) in a column-heater set at 25◦C
(BFO-04 f1, W.O. Electronics) and an aqueous mobile phase
containing 0.1 M sodium phosphate buffer, pH 6.0, 0.13 mM
EDTA mixed with methanol by a high-pressure gradient system
at a flow-rate of 1.2 ml/min (2 pumps L-7100, Merck-Hitachi) in
a step-gradient of 18% methanol for 18 min and 38% methanol
for the rest of the 25 min run. Derivatized amino acids were
detected by a fluorescence detector (L-7480, Merck-Hitachi)
with excitation at 340 nm and emission at 440 nm.
Statistical Analysis
Data are presented as means ± SEM. Differences in
neurochemical parameters were analyzed by one way analysis
of variance (ANOVA) followed by the Bonferroni post hoc test.
Pearson correlation between the parameters were calculated
for the 37 single values of all animals, the 23 single values
of all MPTP monkeys, 12 single values of the asymptomatic
or recovered MPTP monkeys and the 14 single values of the
controls. All the analysis included in the manuscript and those
included in previous related articles were blinded.
RESULTS
Monkeys were classified in four motor states at least 1 month
after the last MPTP administration: the asymptomatic (n = 6)
never displayed PD-type motor symptoms; the recovered (n = 6)
who had motor symptoms with a maximum Kurlan scale of
11.3± 1.5, but recovered to normal behavior and were sacrificed
15.3 ± 0.4 weeks after recovery; the mildly parkinsonian (n = 6)
displayed motor symptoms of a Kurlan of 16± 1.2 to 12.3± 0.6;
and the severely parkinsonian (n = 5) with Kurlan values of
20± 0.7 to 19.5± 1 before sacrifice (Blesa et al., 2012). The mean
values of the OB weights of the 4 motor stages and the controls
varied between 23 ± 5 mg and 28 ± 2 mg and did not differ
significantly.
The tissue contents of the biogenic monoamines NA, DA
and 5-HT in the OB of controls was quite similar ranging
from 0.192 µg/g to 0.239 µg/g tissue weight. NA was not
significantly changed as compared to controls in the various
states resulting from MPTP administration with a three fold
higher level in severely parkinsonian than in mildly parkinsonian
monkeys (Table 1). DA levels were increased in all groups
after MPTP administration (Table 1), with the highest and
significant increase by 96% in the recovered group and gradually
smaller, insignificant increases in the asymptomatic group (51%)
and the parkinsonian group (37% and 43% in mildly and
severely, respectively). Single values reveal an overlap between
the recovered/asymptomatic and the control group, however
at least half of the values were above the range of control
values (Figure 1). 5-HT and its metabolite 5-HIAA were not
significantly affected by MPTP treatment at any of the various
states after administration (Table 1).
Turnover of DA and 5-HT in the OB could be estimated
by molar ratios calculated from single values DOPAC/DA,
HVA/DA and 5-HIAA/5-HT. Neither DOPAC nor HVA values
were affected by MPTP treatment, however the molar ratio
DOPAC/DA was significantly reduced in the recovered group
as compared to control (Table 2), whereas the DA turnover
parameter HVA/DA was unchanged after MPTP administration,
as well as the parameter for 5-HT turnover 5-HIAA/5-HT.
None of the mean values of the amino acid neurotransmitters
GABA, aspartate, glutamate, taurine nor glycine was affected
by MPTP significantly at any of the states after administration
(Table 3). Correlation analysis of the single values between the
14 parameters all over the five experimental groups resulted in a
Bonferroni-corrected significant Pearson correlation coefficient
between HVA and taurine, HVA and glutamate, HVA/DA
and glutamate, aspartate and taurine and between aspartate
and glutamate (Table 4). None of these correlations were
significant if calculated for the 14 single values in the
control group. However, correlation analysis in the four
TABLE 1 | Monoamine neurotransmitter parameters (µg/gww) in the olfactory bulb (OB) in various stages of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
parkinsonism.
Substance Control Asymptomatic Recovered Mildly parkinsonian Severely parkinsonian
NA 0.192 ± 0.026 (14) 0.178 ± 0.031 (6) 0.157 ± 0.045 (6) 0.092 ± 0.041 (6) 0.291 ± 0.028 (5)∗
DA 0.194 ± 0.015 (14) 0.294 ± 0.044 (6) 0.381 ± 0.078 (6)# 0.266 ± 0.014 (6) 0.278 ± 0.028 (5)
DOPAC 0.029 ± 0.002 (14) 0.032 ± 0.006 (6) 0.028 ± 0.005 (6) 0.028 ± 0.004 (6) 0.030 ± 0.003 (5)
HVA 0.306 ± 0.035 (14) 0.383 ± 0.074 (6) 0.347 ± 0.057 (6) 0.259 ± 0.026 (6) 0.365 ± 0.050 (5)
5-HT 0.239 ± 0.019 (14) 0.189 ± 0.015 (6) 0.236 ± 0.017 (6) 0.199 ± 0.024 (6) 0.327 ± 0.051 (5)
5-HIAA 0.046 ± 0.004 (14) 0.036 ± 0.008 (6) 0.036 ± 0.003 (6) 0.036 ± 0.004 (6) 0.055 ± 0.007 (5)
∗p < 0.05 vs. Mildly parkinsonian, #p < 0.05 vs. Control (analysis of variance, ANOVA followed by Bonferroni t-tests). Values are given as mean ± SEM (n).
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FIGURE 1 | Individual values (circles) and mean values (horizontal lines) of
dopamine (DA) in the olfactory bulb (OB) of Macaca fascicularis monkeys
staying after MPTP treatment either asymptomatic (n = 6), recovered from
parkinsonian symptoms (n = 6), mildly (n = 6) or severely parkinsonian (n = 5)
and controls (n = 14). ∗P < 0.05 vs. control.
MPTP administration groups resulted still in a significant
Pearson correlation coefficient between HVA and taurine,
whereas correlation analysis in the two MPTP groups without
parkinsonian symptoms at the time of analysis (asymptomatic
and recovered group) revealed significant correlation between
aspartate and taurine.
DISCUSSION
The main finding of our study is that neither the tissue content
of the monoamine neurotransmitters NA, DA and 5-HT nor of
their metabolites is significantly reduced at any of the various
states after MPTP administration. In the same monkeys reported
here striatal DA was found reduced by more than 90% (caudate
in recovered group) up to 98% (caudate and putamen in the
mildly and severely parkinsonian group; Blesa et al., 2012) and
thalamic NA by more than 54% (ventrolateral nucleus in the
parkinsonian groups) up to 70% (ventroanterior nucleus in the
severely parkinsonian group; Pifl et al., 2013). In a previous study
on rhesus monkeys in a group of animals assessed asymptomatic
3–5 weeks after MPTP administration widespread loss of NA
and 5-HT was observed in cortical areas with a very similar
dissectional and analytical approach (Pifl et al., 1991) and some
of these losses are also observed in the Macaca fascicularis
used in this study (unpublished observation). This means that
noradrenergic and serotoninergic innervation of the OB by locus
coeruleus and raphe nucleus, respectively, react quite differently
to MPTP as compared to fibers innervating thalamic and cortical
brain areas.
The second novel finding of this study is that DA
tissue content in OB is increased very early throughout all
MPTP treatment groups with nearly doubling of the levels
in the recovered group. The most obvious explanation is an
increase of the number of intrinsic DA neurons in the OB
reported in several studies on PD (Huisman et al., 2004;
Mundiñano et al., 2011) and in animal models with nigrostriatal
dopaminergic denervation by MPTP (Yamada et al., 2004;
Belzunegui et al., 2007) or by 6-hydroxydopamine (Winner
et al., 2006; Chiu et al., 2014). The 51% DA increase in
the asymptomatic and the robust 96% DA increment in
the recovered group is in keeping with neurogenesis or
formation by phenotype change of DA cells in the OB in
the presence of mild/moderate nigrostriatal degeneration in
these monkeys (Blesa et al., 2012). Assuming that primates
behave similarly to rodents, where a dopaminergic nigro-
olfactory projection was described recently (Höglinger et al.,
2015), the small increase of DA levels in the mildly and
severely parkinsonian groups might result from a combination of
increased numbers of olfactory DA cells and a more profound
loss of potential nigro-olfactoral nerve terminals (Figure 2).
Since all nigral dopaminergic axons innervating the rat OB
appear to branch into the striatum (Höglinger et al., 2015), the
lower numbers of nigral DA cells in our parkinsonian than in
the recovered monkeys (Blesa et al., 2012) might then let expect
lower DA innervation of the OB in these groups, assuming
that the nigro-olfactory projection is present in macaques
as well as in rats.
The increase of dopaminergic periglomerular neurons
in neurodegenerative disorders was recently explained by
potentially reduced noradrenergic and serotonergic inputs with
a subsequent reduced inhibitory modulation of the mitral cells
resulting in hyperactivity, which might then induce an increase
in the dopaminergic periglomerular neurons as a compensatory
plastic response to the lack of centrifugal inhibition (Mundiñano
et al., 2011). Our data of unchanged NA and 5-HT levels
in the recovered group as compared to controls do not
support such an explanation for increased DA neurons in the
OB, however a potential cholinergic denervation, supporting
centrifugal inhibition in a recent study on PD patients and
MPTP-treated (Mundiñano et al., 2013), was not determined in
our study.
Interestingly, DA increase was not accompanied by equivalent
increases in the DA metabolites DOPAC and HVA, which
TABLE 2 | Dopamine (DA) and serotonin (5-hydroxytryptamine, 5-HT) turnover (molar ratio) in the OB in various stages of MPTP parkinsonism.
Molar ratio Control Asymptomatic Recovered Mildly parkinsonian Severely parkinsonian
DOPAC/DA 0.138 ± 0.012 (14) 0.099 ± 0.013 (6) 0.076 ± 0.013 (6)∗ 0.097 ± 0.013 (6) 0.104 ± 0.002 (5)
HVA/DA 1.34 ± 0.12 (14) 1.06 ± 0.12 (6) 0.90 ± 0.17 (6) 0.82 ± 0.08 (6) 1.12 ± 0.13 (5)
5-HIAA/5-HT 0.182 ± 0.013 (14) 0.170 ± 0.027 (6) 0.143 ± 0.015 (6) 0.170 ± 0.017 (6) 0.165 ± 0.023 (5)
∗p < 0.05 vs. Control (ANOVA followed by Bonferroni t-tests). Values are given as mean ± SEM (n).
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TABLE 3 | Amino acid neurotransmitters (µg/gww) in the OB in various stages of MPTP parkinsonism.
Amino acid Control Asymptomatic Recovered Mildly parkinsonian Severely parkinsonian
GABA 351 ± 20 (14) 379 ± 26 (6) 400 ± 40 (6) 379 ± 26 (6) 454 ± 13 (5)
Aspartate 230 ± 9 (14) 237 ± 18 (6) 231 ± 16 (6) 218 ± 11 (6) 232 ± 21 (5)
Glutamate 832 ± 29 (14) 757 ± 59 (6) 775 ± 39 (6) 789 ± 35 (6) 833 ± 25 (5)
Taurine 843 ± 32 (14) 881 ± 80 (6) 877 ± 52 (6) 827 ± 31 (6) 926 ± 45 (5)
Glycine 112 ± 4 (14) 99 ± 4 (6) 113 ± 13 (6) 103 ± 5 (6) 107 ± 6 (5)
Values are given as mean ± SEM (n).
TABLE 4 | Correlation between parameters with significant Pearson correlation coefficients after Bonferroni correction.
All five treatment groups All four MPTP groups Asymptomatic and recovered MPTP groups
Correlation coefficient P-value Correlation coefficient P-value Correlation coefficient P-value
HVA and taurine 0.663 0.00000765 0.676 0.000401 – –
HVA and glutamate 0.590 0.000121 – – – –
HVA/DA and glutamate 0.619 0.0000449 – – – –
Aspartate and taurine 0.551 0.000410 – – 0.895 0.0000823
Aspartate and glutamate 0.633 0.0000257 – – – –
explain the decrease in the turnover ratios which turned out
to be significant in the case of DOPAC/DA in the recovered
group. This discrepancy between a high DA increase and
a lower increment of HVA and unchanged DOPAC in OB
tissue with potential dopaminergic neurogenesis is surprising
since the SN with its intrinsic dopaminergic neurons contains
relatively higher levels of DA metabolites than striatum with
its dopaminergic nerve endings but no intrinsic DA neurons
(Pifl and Hornykiewicz, 2006). This would have led to expect
a substantial increase of metabolites in the OB by an increased
number of dopaminergic cell bodies. Therefore, a profound
FIGURE 2 | Schematic presentation of a hypothesis for the higher increase of
DA in OB of recovered than in parkinsonian MPTP-treated monkeys. (A) DA
nerve endings from the substantia nigra (SN) and intrinsic DA neurons
contribute to DA tissue levels in the OB. In recovered monkeys (B) DA levels
are increased due to more intrinsic DA neurons. In parkinsonian monkeys (C)
DA levels are lower than in recovered due to an additional loss of nigral
dopaminergic neurons innervating the OB.
difference can be assumed between newly born dopaminergic
neurons in the OB and dopaminergic neurons in the SN in terms
of metabolism. For example, synaptic vesicles with vesicular
monoamine transporter within newly formed dopaminergic
neurons in the OB as opposed to the endogenous without
it (Peter et al., 1995; Weihe et al., 2006) might explain the
high level of DA relative to DA metabolites by preventing
cytosolic degradation and a high resistance of these cells to toxic
effects of MPTP similarly to mice overexpressing the vesicular
monoamine transporter which were reported to be protected
from MPTP neurotoxicity (Lohr et al., 2014). Furthermore,
the OB has dramatically less DA transporter compared with
striatum (Mitsumoto et al., 2005; Cockerham et al., 2016)
which is consistent with the resistance of these neurons (in
all species) to destruction by either 6-hydroxydopamine or
MPTP. In fact, intranasal MPTP administration in rat also
leaves many dopaminergic periglomerular neurons survive,
whereas dopaminergic neurons of the SN were strongly
affected confirming a different vulnerability to MPTP (Prediger
et al., 2009). As far as potential interference of high DA
levels with normal OB function is concerned the low DA
turnover based on metabolite to DA ratios could indicate
a defective neurotransmission of the additional dopaminergic
neurons.
Out of all the neurotransmitter related substances in OB
analyzed in this study, taurine had the highest tissue levels
which is in agreement with a report on taurine content of
eight different major rat CNS areas with the highest value
in the OB which was quite similar to the present values in
monkeys (Collins, 1974). A range of cortical and subcortical
regions in our Macaca fascicularis also contained much lower
taurine levels than OB (unpublished results). The significant
correlations of single values of HVA with taurine calculated over
all four MPTP groups and of aspartate with taurine over the
asymptomatic and the recovered but not in the control group
suggest an interaction between DA metabolism and taurine as
well as excitatory activity and taurine in the neuronal network of
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the OB triggered by the dopaminergic neurotoxin. MPTP does
not shift the levels of these parameters to significantly changed
mean values in particular groups of MPTP exposed monkeys but
seems to cause perturbations with parallel individual deflections
in the single animals. Although correlations do not imply
causation, it is interesting in this respect that intraventricular
taurine increased striatal and hypothalamic DOPAC in the rat
(Panula-Lehto et al., 1992), the main DA metabolite in this
species, and a neuroinhibitory effect of taurine was observed
in the OB with selectivity for mitral and tufted cells (Belluzzi
et al., 2004) which are glutamatergic cells (Nagayama et al.,
2014).
CONCLUSION
Our observation of a substantial increase of DA tissue levels
confirms and expands to the non-human primate a paradoxical
reaction of DA in the OB in parallel with progressive nigro-
striatal dopaminergic lesion. We also show that no other
monoamine neurotransmitters or established and potential
amino acid neurotransmitters are affected by MPTP. This first
neurochemical investigation of OB in various stages after MPTP
administration suggests that the effect on DA seems to be an
early phenomenon in PD, not requiring profound nigrostriatal
neurodegeneration or the appearance of PD motor features.
Furthermore, this study supports the accumulating evidence
that neurotransmitters play a crucial role in determining
survival and differentiation of newly generated neurons
in the OB.
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